SCHEMBL1102946

SCHEMBL1102946

c1ccc2c(-c3ccc4c5ccccc5c5ccccc5c4c3)c3ncccc3c(-c3ccc4c5ccccc5c5ccccc5c4c3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HSP90AA1 P07900 7/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.38
CCR1 P32246 3/20 0.36
CCR8 P51685 3/20 0.36
KDM4E B2RXH2 6/20 0.35
TP53 P04637 5/20 0.35
HTT P42858 5/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
TDP1 Q9NUW8 5/20 0.35
LMNA P02545 5/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
ALOX15 P16050 4/20 0.35
MAPT P10636 4/20 0.35
SLC6A2 P23975 3/20 0.35
USP2 O75604 3/20 0.35
CYP3A4 P08684 3/20 0.35
HIF1A Q16665 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16433702 0.89 HSP90AA1 (0.45) ALDH1A1HSP90AA1L3MBTL1NPC1CCR1
SCHEMBL1103081 0.83 L3MBTL1 (0.42) ALDH1A1HSP90AA1L3MBTL1NPC1KDM4E
SCHEMBL1103115 0.83 L3MBTL1 (0.42) ALDH1A1HSP90AA1L3MBTL1NPC1KDM4E
SCHEMBL1103109 0.83 L3MBTL1 (0.42) ALDH1A1HSP90AA1L3MBTL1NPC1KDM4E
SCHEMBL1103120 0.83 L3MBTL1 (0.42) ALDH1A1HSP90AA1L3MBTL1NPC1KDM4E
SCHEMBL1102913 0.83 TOP1 (0.38) ALDH1A1HSP90AA1L3MBTL1NPC1TOP1
SCHEMBL1103074 0.83 CYP17A1 (0.45) ALDH1A1HSP90AA1L3MBTL1NPC1CCR1
SCHEMBL1102860 0.83 CYP17A1 (0.45) ALDH1A1HSP90AA1L3MBTL1NPC1CCR1
SCHEMBL1103108 0.82 ESR1 (0.41) ALDH1A1HSP90AA1L3MBTL1NPC1CCR1
SCHEMBL1103113 0.82 ESR1 (0.41) ALDH1A1HSP90AA1L3MBTL1NPC1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885HSP90AA1 4884/4885L3MBTL1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.